Question 1

What is Alnylam Pharmaceuticals, Inc.'s WACC?

Accepted Answer

Alnylam Pharmaceuticals, Inc. (ALNY) has a Weighted Average Cost of Capital (WACC) of 6.18%. This is calculated using a Cost of Equity of 6.18% (via CAPM with a beta of 0.46) and a pre-tax Cost of Debt of 5.00%, with an equity weight of 100.00% in the capital structure.

Question 2

Is Alnylam Pharmaceuticals, Inc.'s WACC high or low?

Accepted Answer

Alnylam Pharmaceuticals, Inc.'s WACC of 6.18% is below the typical range of 8-12% for most companies, indicating relatively low cost of capital and lower risk. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is Alnylam Pharmaceuticals, Inc.'s WACC calculated?

Accepted Answer

Alnylam Pharmaceuticals, Inc.'s WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 6.18% is derived from the CAPM model using a beta of 0.46. The pre-tax Cost of Debt (Rd) is 5.00%. The capital structure is 100.00% equity and 0.00% debt.

Alnylam Pharmaceuticals, Inc. (ALNY) — WACC 分析

WACC 构成

解读

Alnylam Pharmaceuticals, Inc.（ALNY）WACC：6.18%

WACC计算器

Alnylam Pharmaceuticals, Inc.（ALNY） WACC 解读

ALNY 公司分析

ALNY DCF 估值

继续做同行对比